Clinical DevelopmentAssets from Innate Pharma's ANKET and ADC franchises hold promise of definitive early-phase clinical catalysts and growth upside.
Research And DevelopmentPreclinical data with IPH45 shows promise as an effective ADC, with a high drug-antibody-ratio (DAR) of 8, suggesting a potent therapeutic capability.
Strategic OwnershipInnate retains ownership of the oncology ADCs and a CD20-targeted ANKET, indicating a different risk profile with potentially higher rewards.